Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways

The anti-CD20 monoclonal antibodies rituximab and obinutuzumab differ in their mechanisms of action, with obinutuzumab evoking greater direct B cell death. To characterize the signaling processes responsible for improved B cell killing by obinutuzumab, we undertook a phosphoproteomics approach and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Edelmann, Jennifer, Dokal, Arran D., Vilventhraraja, Emma, Holzmann, Karlheinz, Britton, David, Klymenko, Tetyana, Döhner, Hartmut, Cragg, Mark, Braun, Andrejs, Cutillas, Pedro, Gribben, John G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878992/
https://www.ncbi.nlm.nih.gov/pubmed/33615197
http://dx.doi.org/10.1016/j.isci.2021.102089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878992/
https://www.ncbi.nlm.nih.gov/pubmed/33615197
http://dx.doi.org/10.1016/j.isci.2021.102089

Ejemplares similares